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Abstracts / Urological Science 26 (2015) S50eS81 S71Materials and Methods: We retrospectively reviewed 26 cases with renal
tumors managed by open partial nephrectomy at our institution from
January 2008 to October 2013. R.E.N.A.L., PADUA and centrality index
scores were assigned according to the described protocols for those sys-
tems. We evaluated the association between scoring systems and both
early and late postoperative functional outcome.
Results: The mean age of study population was 56 years old. Of the pa-
tients 18 (69%) were male. Mean tumor size was 4.04cm. Each scoring
system performed signiﬁcant correlation with both early and late func-
tional outcome (p < 0.05), whereas R.E.N.A.L nephrometry and PADUA
classiﬁcation showed high correlation (-0.715 and -0.721) and centrality
index showed moderate correlation (0.451). Single anatomical parameter
as diameter of tumor does not correlate with functional outcome signiﬁ-
cantly. (p ¼ 0.974 in one day after surgery and p ¼ 0.865 in one year after
surgery).
Conclusion: R.E.N.A.L., PADUA and centrality index scores were inversely
associated with renal function preservation after partial nephrectomy. In
this regard it is possible to use theses scoring systems preoperatively to
gauge the magnitude of functional decrease.
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Purpose: Ductal adenocarcinoma of the prostate is a rare histological
subtype of primary prostate cancer. Previous reports had showed that
ductal adenocarcinoma of the prostate had a distinct behavior when
compared to common acinar adenocarcinoma. About prostate acinar
adenocarcinoma, previous studies had showed different incidence, risk,
and prognostic condition, but due to the rarity of prostate ductal adeno-
carcinoma, the reports of prostate ductal adenocarcinoma in Asian popu-
lation are still limited in small case series/reports. We intended to share
our experiences and analyzed the treatment outcome.
Materials and Methods: Patients with diagnosis of prostate ductal
adenocarcinoma in our hospital during 2001~2014 were retrospectively
reviewed. The initial symptoms, PSA level, treatment, and follow-up con-
dition were retrieved for analysis.
Results: 18 patients had been diagnosed with prostate ductal adenocar-
cinoma during the period. Themean age of presentationwas 75.5 years old
(62-85). The most presenting symptoms is LUTS with elevated PSA. The
median initial PSA level was 21.67ng/ml (2.47-629). The mean follow-up
time was 29.1 months (2-126). 5 patients had radiographic distant
metastasis or invasion to adjacent organ at initial staging. 12 patients were
diagnosed by transrectal sonography-guided prostate biopsy; 2 patients
were diagnosed by transurethral resection of prostate, 1 patient was
diagnosed by transurethral resection of bladder tumor, and 3 patients
received radical prostatectomy due to localized disease. Among these 3
patients, 2 patients were current disease-free with 14, 24 month follow-
up. Another patient presented with bone metastasis 20 months after RRP
and died of the disease 34 months after the operation despite hormone
therapy. Totally only 5 patients had survived at least 3 years.
Conclusion: Ductal prostate adenocarcinoma tends to present with
advanced clinical stage, relatively lower PSA levels then common prostate
acinar carcinoma and the clinical behavior seems more aggressive. Clini-
cally, we should regard these patients as a distinct group, which different
from common prostate acinar adenocarcinoma patients.
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Purpose: NAD(P)H:quinine oxidoreductase (NQO1) plays an important
role in the metabolism of several carcinogens contained in cigarettes.
Inducible nitric oxide synthase (iNOS) expression had been detected in
urinary bladder tumors. The aim of this study was to investigate the
interaction of iNOS and NQO1 on bladder cancer (BC) risk stratiﬁed by
cigarette smoking status.
Materials and Methods: A total of 159 BC patients and 150 cancer-free
controls were recruited from December 2003 to November 2004.
Genotyping of NQO1 rs1800566 polymorphism and iNOS (CCTTT)n
pentanucleotide repeat polymorphism was determined using the
polymerase chain reaction-restricted fragment length polymorphism
and sequencing method. The odds ratio and 95% conﬁdence interval
(CI) were calculated as a measure of the joint effect of NQO1 rs1800566
and iNOS (CCTTT)n polymorphisms on BC risk among cigarette
smokers.
Results: Compared with study participants carrying the C/C genotype of
NQO1 gene, those with C/T and T/T genotypes had a signiﬁcantly
increased BC risk of 1.8 (95% CI ¼ 1.1-2.9). Among cigarette smokers,
those who carried the 12-repeat allele of iNOS (CCTTT)n polymorphism
had a signiﬁcantly increased BC risk of 2.7 (95% CI ¼ 1.0-6.7). Further-
more, a signiﬁcant combined effect of the C/T and T/T genotypes of
NQO1gene and the 12-repeat allele of iNOS (CCTTT)n repeat poly-
morphism on BC was found among cigarette smokers (odds ratio ¼ 4.4,
95% CI ¼ 1.3-14.9).
Conclusion: Our ﬁndings suggest that a signiﬁcant combined effect of
NQO1 C/T and T/T genotypes and the 12-repeat allele of iNOS (CCTTT)n
polymorphism on BC exists, especially in those with the habit of cigarette
smoking.
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Purpose: Interleukin-18 (IL-18) is an 18-kDa cytokine and has similar
structural and functional properties with interleukin-1. IL-18 is produced
by various immune and non-immune cells and serum IL-18 level is re-
ported to have prognostic signiﬁcance in several types of cancers. We
explored the effect of IL-18 gene polymorphisms on the susceptibility of
urothelial cell carcinoma (UCC) in Taiwan.
Materials and Methods: We recruited 283 patients (186 men and 97
women, with a mean age of 68.59 years) at Taichung Veterans General
Hospital in Taichung, Taiwan. Patients were enrolled as a patient group in
2011e2012. All patients have pathology proved UCC of upper urinary
tract or urinary bladder. Meanwhile, during the same study period, 283
age- and gender-matched individuals were enrolled as the controls that
entered the physical examination. Personal information and character-
istics collected from the study subjects using interviewer administered
questionnaires contained questions involving demographic characteris-
tics and the status of cigarette smoking. Medical information for the
cases was obtained from their medical records, and included TNM clin-
ical staging, lymph node involvement, and histologic grade.Allelic
discrimination of -607A/C (rs1946518) and -137G/C (rs187238) poly-
morphisms of the IL-18 gene was assessed by a real-time PCR with the
TaqMan assay.
Results: After adjusting for other co-variants, the individuals carrying at
least one C allele at rs187238 had a 1.617-fold risk of developing UCC than
did wild-type (GG) carriers. Furthermore, the smoking individuals who
Abstracts / Urological Science 26 (2015) S50eS81S72carried at least one C allele at rs187238 had a 2.760efold risk of UCC.
However, the rs1946518 and rs187238 polymorphisms of the IL-18 gene
did not affect tumor stage among the UCC patients.
Conclusion: The rs187238 polymorphic genotypes of IL-18 might
contribute to the susceptibility of UCC and the synergic effect of smoking
was also demonstrated.
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HEMATURIA WITH BLADDER TAMPONADE AND RENAL FAILURE DUE
TO GALLBLADDER CANCER METASTASIS
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Introduction: There are many possible causes of hematuria including:
urinary tract infection, urolithiasis, tumor in kidney or bladder, exercise,
drug, bleeding disorder or trauma. Herein we report a case of hematuria
with bladder tamponade due to gallbladder cancer metastasis
Case report: A 61-year-old women presented with gross hematuria,
nausea, vomiting to our ER for help. According to the statement of her, DM,
CRI, gallbladder stone, cancer post operation. Sonography revealed bladder
tamponade and left hydronephrosis. Due to poor condition, CT scan was
performed and revealed much bladder clot, left hydronephrosis, ascites
and favored carcinomatosis. Emergent cystoscopy removed blood and
bladder tumor was noted. TURBT was performed and pathology revealed
gallbladder cancer metastasis
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Purpose: Visfatin, a newly discovered adipocytokine, is a pro-inﬂamma-
tory cytokine. This study aimed to evaluate the predictive value of visfatin
on prognosis of patients with upper tract urothelial carcinoma.
Materials andMethods: One-hundred and ﬁve patients (median age¼ 64,
range ¼ 24-84 years) were included in this study. Visfatin expression in
upper tract urothelial carcinoma tissues was analyzed by immunohisto-
chemistry. Visfatin expression was correlated with clinicopathologic var-
iables using the c2 test. The prognostic value of visfatin for recurrence-free
and cance-speciﬁc survival was evaluated by Kaplan-Meier estimates, and
the signiﬁcance of differences between curves was evaluated by the log-
rank test. Cox regression model was also used to evaluate the hazard ratios
of visfatin on survival.
Results: High visfatin expression in upper tract urothelial carcinoma tis-
sues was signiﬁcantly correlated with tumor stage (p ¼ 0.001), grade
(p ¼ 0.007) and p53 expression (p ¼ 0.07). High visfatin expression was
associated with poor recurrence-free and cancer-speciﬁc survival. Cox
regression analysis also revealed that visfatin is an independent predictor
of recurrence-free (HR ¼ 3.22, p ¼ 0.009) and cancer-speciﬁc survival
(HR ¼ 5.74, p ¼ 0.023).
Conclusion: Our ﬁndings indicated that higher visfatin expression is a
potential biomarker to predict patient survival. Further study is necessary
to investigate the molecular mechanisms of visfatin involved in the
cancerous processes of upper tract urothelial carcinoma.NDP088:
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Purpose: Signal transducers and activators of transcription (STATs) play an
important role in gene regulation, cell proliferation and differentiation.We
aimed to establish the relationship between STAT3 expression and the
prognosis of upper tract urothelial carcinoma (UTUC).
Materials and Methods: This study retrospectively reviewed 100 patients
with pathologically conﬁrmed UTUC at Kaohsiung Medical University
Hospital. We quantify the expressions of STAT3 in cancer cells by immu-
nohistochemistry method, and determine the clinicopathologic signiﬁ-
cance between expression of STAT3 and prognostic outcome in patients
with UTUC.
Results: High STAT3 expression was detected in 52% of whole UTUC pa-
tients. High STAT3 expression was associated with poor recurrence-free
(p ¼ 0.018) and overall survival (p ¼ 0.026). In the advanced cancer
(stageT3/T4), STAT3 expression is the only independent prognostic factor
for recurrence-free survival (hazard ratio ¼ 5.91, p ¼ 0.01) and cancer-
speciﬁc survival (hazard ratio ¼ 8.83, p ¼ 0.039).
Conclusion: In UTUC, the STAT3 can be a potential prognostic marker for
cancer recurrence and survival, especially in the advanced stage.
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Purpose:We present our experience with the clinical feature, efﬁcacy and
outcome of comparison of partial nephrectomy and radiofrequency abla-
tion (RFA) for small renal tumors in the manner of Preoperative Aspects
and Dimensions Used for an Anatomical (PADUA) Classiﬁcation as a min-
imal invasive treatment in VGHKS
Materials and Methods: A total of 78 patients in 15 years with small renal
tumors were enrolled. We use Preoperative Aspects and Dimensions Used
for an Anatomical (PADUA) Classiﬁcation for renal tumor classiﬁcation and
compared PN (42 patients) and RFA (36 patients) with clinical outcome
(local recurrence-free, metastases-free, and overall survival rates), RFA
procedure (RFA needle, No. of treatment, Anesthesia, complication), renal
function deterioration after procedure and pathology report. We also use
clustered needle or switch mode control of RFA and D5W instillation for
separating bowel loop.
Results: The median value of the PADUA score was 7.5 (IQR: 7e9), which is
no signiﬁcant difference between two groups. Of the 56 cT1a patients, 32
underwent PN, 24 underwent RFA. In this cohort, local recurrence-free
survival, metastases-free survival were similar among the two treatments
(p¼ 0.53 / 0.46). Of the 22 cT1b patients, 10 patients underwent PN, and 12
patients were managed with RFA. In this cohort, local recurrence-free
survival (p ¼ 0.76) and metastases-free survival (p ¼ 0.51) were similar
between PN and RFA. In both the cT1a and cT1b groups, PN patients were
signiﬁcantly younger, with lower Charlson scores and had superior overall
survival (p < 0.001 for all). In the RFA group, all patients have been biopsy
